Vertex Pharmaceuticals Incorporated VRTX
526.19
3.81
0.73%
as of 25 Sep
- Market cap
- $132.3B
- P/E
- 30.4×
Follow VRTX
Indexes
indicate stock being part of an index,
Growth Flags
show if company had growth for consecutive years
Vertex Pharmaceuticals Incorporated (VRTX) Return on assets
Vertex Pharmaceuticals Incorporated's return on assets over the twelve months to 30 June 2026 was 17.1%, up 0.7 percentage points from fiscal 2025 (16.4%). Over the past ten years it has ranged from −23.0% (fiscal 2015) to 42.8% (fiscal 2018); the current reading is higher than 55% of that period. That is above the Biotechnology industry median of −49.2% and above the Healthcare sector median of −30.9%.
Return on assets, annual
Annual
| Period | Return on assets | Change (points) |
|---|---|---|
| FY2025 | 16.4% | 18.78 |
| FY2024 | −2.37% | (20.08) |
| FY2023 | 17.7% | (3.33) |
| FY2022 | 21.0% | 2.44 |
| FY2021 | 18.6% | (8.42) |
| FY2020 | 27.0% | 10.86 |
| FY2019 | 16.2% | (26.67) |
| FY2018 | 42.8% | 34.65 |
| FY2017 | 8.18% | 12.33 |
| FY2016 | −4.15% | 18.87 |
Against its own ten years
Low −23.0%
High 42.8%
Ten-year median
16.4%
Current reading's percentile
55
Return on assets against peers
| Company | Return on assets |
|---|---|
| ARGX argenex SE compare | 20.0% |
| VRTX Vertex Pharmaceuticals Incorporated | 17.1% |
| ALNY Alnylam Pharmaceuticals, Inc. compare | 15.3% |
| REGN Regeneron Pharmaceuticals, Inc. compare | 10.8% |
| ONC BeOne Medicines Ltd. - Sponsored ADR compare | 8.47% |
| RPRX Royalty Pharma PLC compare | 4.26% |
| MRNA Moderna, Inc. compare | −27.4% |
| INSM Insmed, Inc. compare | −38.2% |
| RVMD Revolution Medicines, Inc. compare | −52.4% |
| Biotechnology industry median | −49.2% |
| Healthcare sector median | −30.9% |
| Market median | 0.00% |
What Return on assets is
ROA tells an investor how much profit a company earns for shareholders from the assets it uses to run its business.
Annual: Net Income Allotted to Shareholders ÷ Average Assets; TTM: Net Income Allotted to Shareholders ÷ Average Assets (latest quarter)
More on VRTX
- Revenue
- Net income
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- Return on equity
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- The full statement